The Latest on CRI’s START (Strategic Antiretroviral Timing) study

CRI is now recruiting trial participants for the international START (Strategic Timing of Antiretroviral Treatment) study. START will attempt to answer the question, “When should I start taking HIV medication?” In its initial phase, START will enroll 900 participants from 22 countries around the world. If this first phase is successful, enrollment will expand to include 4,000 participants and additional countries. The entire study is expected to take about six years. CRI is one of twenty-two sites in the United States and one of only two sites in New England.

Julie Marston, CRI’s Executive Director, says that “the START study is another example of CRI’s participation in leading-edge research that can make a global impact.” Marston notes that “the more international the sample, the more confidence we can have about the outcomes. We can answer questions in a way that helps both the local community and the larger global community.”

For more information about the START trial, please visit. If you would like to know more about study participation visit or contact Sandy Sheble Hall at 617.502.1776 or shall@crine.org.